Geoff MacKay, Avrobio CEO

Avro­bio halts PhII study for Fab­ry dis­ease in an­oth­er set­back, shut­ter­ing lead pro­gram

An oft-trou­bled Fab­ry dis­ease pro­gram got the axe Tues­day as its par­ent com­pa­ny will shut down de­vel­op­ment af­ter re­view­ing some new Phase II da­ta. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.